# Gefitinib in Treating Patients With Cervical Cancer

> **NCT00049556** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Cervical Cancer
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** gefitinib
- **OTHER:** immunohistochemistry staining method
- **OTHER:** surface-enhanced laser desorption/ionization-time of flight mass spectrometry
- **PROCEDURE:** biopsy
- **PROCEDURE:** sentinel lymph node biopsy

## Key facts

- **NCT ID:** NCT00049556
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049556, "Gefitinib in Treating Patients With Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00049556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*